

1 **Prenatal exposure to environmental contaminants is associated with altered**
2 **cord serum metabolite profiles in future immune-mediated diseases**

3

4 Bagavathy Shanmugam Karthikeyan,^{1,2} Tuulia Hyötyläinen,¹ Tannaz Ghaffarzadegan,¹ Eric
5 Triplett,³ Matej Orešič,^{2,4,*} Johnny Ludvigsson⁵

6

7 ¹School of Science and Technology, Örebro University, SE-702 81 Örebro, Sweden

8 ²School of Medical Sciences, Faculty of Medicine and Health, Örebro University, SE-702 81
9 Örebro, Sweden

10 ³Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences
11 University of Florida, Gainesville, 32611-0700, FL, USA

12 ⁴Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, FI-20520,
13 Finland

14 ⁵Crown Princess Victoria's Children's Hospital and Division of Pediatrics, Department of
15 Biomedical and Clinical Sciences, Linköping University, Linköping, SE-581 85, Sweden

16

17 *Correspondence:

18

19 Matej Orešič; School of Science and Technology, Örebro University, 702 81 Örebro, Sweden.

20 Email: matej.oresic@oru.se; Phone: +46 76 9464459. ORCID ID: 0000-0002-2856-9165

21 (editorial correspondence)

22

23

24 **Abstract**

25 Prenatal exposure to environmental contaminants is a significant health concern because it has the
26 potential to interfere with host metabolism, leading to adverse health effects in early childhood
27 and later in life. Growing evidence suggests that genetic and environmental factors, as well as their
28 interactions, play a significant role in the development of autoimmune diseases. In this study, we
29 hypothesized that prenatal exposure to environmental contaminants impacts cord serum
30 metabolome and contributes to the development of autoimmune diseases. We selected cord serum
31 samples from All Babies in Southeast Sweden (ABIS) general population cohort, from infants who
32 later developed one or more autoimmune-mediated and inflammatory diseases: celiac disease
33 (CD), Crohn's disease (IBD), hypothyroidism (HT), juvenile idiopathic arthritis (JIA), and type 1
34 diabetes (T1D) (all cases, N = 62), along with matched controls (N = 268). Using integrated
35 exposomics and metabolomics mass spectrometry (MS) based platforms, we determined the levels
36 of contaminants and metabolites. Differences in exposure levels were found between the controls
37 and those who later developed various diseases. High contaminant exposure levels were associated
38 with changes in metabolome, including amino acids and free fatty acids. Specifically, we identified
39 marked associations between metabolite levels and exposure levels of deoxynivalenol (DON),
40 bisphenol S (BPS), and specific per- and polyfluorinated substances (PFAS). Our study suggests
41 that prenatal exposure to specific environmental contaminants alters the cord serum metabolomes,
42 which, in turn, might increase the risk of various immune-mediated disease later in life.

43

44 **Keywords:** autoimmune disease; environmental contaminants; exposome; lipidomics;
45 metabolomics; type 1 diabetes.

46

47 **Introduction**

48 Exposure to environmental contaminants contributes to the global burden of many chronic diseases
49 (Chew et al. 2023; Cui et al. 2016; Diseases and Injuries 2020; Landrigan et al. 2016; Shaffer et
50 al. 2019). Over the past few decades, the prevalence of autoimmune diseases increased in both
51 developed and developing countries, resulting in a high disease burden (Berhan et al. 2011;
52 Carstensen et al. 2020; Eaton et al. 2007; Harjutsalo et al. 2013; Patterson et al. 2009).
53 Autoimmune diseases are often manifested in early childhood and are also common among the
54 pregnant mothers (Eaton et al. 2007; Tincani et al. 2016). They are chronic, impact child growth
55 and development and require long-term management and care (Rosenblum et al. 2012; Wilson et
56 al. 2016). Many studies suggest that a combination of genetic predisposition, environmental and
57 maternal factors as well as their interactions play a significant role in the etiology of autoimmune
58 diseases (Ellis et al. 2014; Oresic et al. 2013; Oresic et al. 2008; Rewers and Ludvigsson 2016;
59 Sen et al. 2019; Sen et al. 2020; Sinisalu et al. 2020; Virolainen et al. 2023).

60 Exposure of humans to environmental chemicals begins already during the "sensitive window" of
61 human early development, including the prenatal stage (Buhimschi and Buhimschi 2012;
62 Karthikeyan et al. 2021; Landrigan and Goldman 2011; Robinson and Vrijheid 2015). Prenatal
63 exposure to PFAS and other contaminants have been associated with abnormal metabolism and
64 later progression to autoimmune diseases such as T1D (McGlinchey et al. 2020), CD (Sen et al.
65 2019; Sinisalu et al. 2020), IBD (Filimoniuk et al. 2020) later. PFAS exposure, for instance, alters
66 the levels of phospholipids and contributes to the risk of T1D (McGlinchey et al. 2020). Although
67 most autoimmune diseases share common pathogenicity and genetic risk factors (Ilonen et al.
68 2016; Sen et al. 2019), their underlying pathogenic mechanisms are poorly understood. Beside
69 exposure to environmental chemicals, perinatal factors such as low birth weight (Katsarou et al.
70 2017), the gut microbiome (Belteky et al. 2023; Khan and Wang 2019; Kindgren et al. 2023; Kostic
71 et al. 2015; Vatanen et al. 2018; Weis 2018) and maternal diet (Johnson et al. 2021; Johnson et al.
72 2019; Virtanen et al. 2012) are also attributed to the progression of autoimmune diseases.

73 Given the potential impact of exposure to environmental contaminants and the role of maternal
74 factors in the progression of autoimmune diseases (Hyotylainen et al. 2023), it is important to
75 characterize the prenatal and early-life exposome to better understand the pathogenesis of
76 autoimmune diseases. Herein, we hypothesized that exposure to environmental contaminants
77 impacts cord serum metabolome, which may contribute to the development of one or more
78 autoimmune diseases in the general population cohort (All Babies In Southeast Sweden, ABIS)
79 (Ludvigsson et al. 2001; Nygren et al. 2015). We quantified levels of contaminants and metabolite
80 profiles from cord serum collected at birth, using integrated exposomics and metabolomics
81 approaches. We investigated (i) the levels of exposure and significant differences between controls
82 and cases, (ii) associations of contaminant exposure with cord serum metabolic profiles, and (iii)
83 the impact of contaminant exposure levels on cord serum metabolic profiles.

84 **Materials and methods**

85 **Study design**

86 ABIS, a general population cohort consists of 17000 children born 1st of Oct 1997- 1st of Oct 1999,
87 followed prospectively with regular follow-ups. ABIS is connected to the Swedish National
88 Diagnosis Register which give information about diagnosis of autoimmune disease. Stool samples
89 were collected from ca 1800 individuals at 1 year of age, and microbiome studies have been
90 performed (Belteky et al. 2023; Hyotylainen et al. 2023). The present study includes subjects
91 (N=62) from this group who later developed one or more autoimmune and inflammatory diseases
92 such as celiac disease (CD), Crohns disease (IBD), hypothyroidism (HT), juvenile idiopathic
93 arthritis (JIA) and type1 diabetes (T1D) along with their matching controls (N=268). The cord
94 blood samples collected during birth were subjected to metabolomics analysis. **Fig. 1** summarizes
95 the study design and integrated workflow.

96 This study was performed in accordance with the Declaration of Helsinki. The ABIS study was
97 approved by the Research Ethics Committees of the Faculty of Health Sciences at Linköping

98 University, Sweden, 1997/96287 and 2003/03-092 and the Medical Faculty of Lund University,
99 Sweden (DNR 99227, DNR 99321). All participating parents gave their informed consent to
100 participate in ABIS after oral, written and video information. ABIS connection to national register
101 approved by the Research Ethics Committees of the Faculty of Health Sciences at Linköping
102 University, Sweden, DNR 05-513, and 2018/380-32.

103 **Analysis of metabolome and environmental contaminants**

104 A total of 360 cord blood samples were randomized and analyzed as described below. Shortly, two
105 methods were applied for separate extraction of lipids and polar/semipolar metabolites and the
106 extracts were then analyzed using an ultra-high-performance liquid chromatography quadrupole
107 time-of-flight mass spectrometry (UHPLC-QTOFMS) as described previously (Hyotylainen et al.
108 2023) and the data were processed using MZmine 2.53 (Pluskal et al. 2010). Quantification was
109 performed using calibration curves and the identification was done with a custom data base, with
110 identification levels 1 and 2 (Metabolomics Standards Initiative). Quality control was performed
111 by analyzing pooled quality control samples. In addition, extracted blank samples, standards
112 compounds, and reference plasma (NIST SRM 1950); purchased from the National Institute of
113 Standards and Technology at the US Department of Commerce (Washington, DC, USA)) were
114 analyzed as part of the quality control procedure.

115 *Analysis of molecular lipids*

116 10 µl of serum was mixed with 10 µl 0.9% NaCl and extracted with 120 µl of CHCl₃: MeOH (2:1,
117 v/v) solvent mixture containing internal standard mixture (c = 2.5 µg/ml; 1,2-diheptadecanoyl-sn-
118 glycerol-3-phosphoethanolamine (PE(17:0/17:0)), N-heptadecanoyl-D-erythro-
119 sphingosylphosphorylcholine (SM(d18:1/17:0)), N-heptadecanoyl-D-erythro-sphingosine
120 (Cer(d18:1/17:0)), 1,2-diheptadecanoyl-sn-glycerol-3-phosphocholine (PC(17:0/17:0)), 1-
121 heptadecanoyl-2-hydroxy-sn-glycerol-3-phosphocholine (LPC(17:0)) and 1-palmitoyl-d31-2-
122 oleoyl-sn-glycerol-3-phosphocholine (PC(16:0/d31/18:1)) and, triheptadecanoylglycerol

123 (TG(17:0/17:0/17:0)). The samples were vortexed and let stand on the ice for 30 min before
124 centrifugation (9400 rcf, 3 min). 60 μ l of the lower layer of was collected and diluted with 60 μ l
125 of CHCl₃: MeOH. The samples were kept at -80 °C until analysis.

126 Samples were analyzed by UHPLC-QTOFMS (Agilent Technologies; Santa Clara, CA, USA).
127 The analysis was carried out on an ACQUITY UPLC BEH C18 column (2.1 mm \times 100 mm,
128 particle size 1.7 μ m) by Waters (Milford, USA). The eluent system consisted of (A) 10 mM NH₄Ac
129 in H₂O and 0.1% formic acid and (B) 10 mM NH₄Ac in ACN: IPA (1:1) and 0.1% formic acid.
130 The gradient was as follows: 0-2 min, 35% solvent B; 2-7 min, 80% solvent B; 7-14 min 100%
131 solvent B. The flow rate was 0.4 ml/min.

132 The following steps were applied in data processing with MZmine 2.53: (i) Mass detection with a
133 noise level of 1000, (ii) Chromatogram builder with a minimum time span of 0.08 min, minimum
134 height of 1000 and a m/z tolerance of 0.006 m/z or 10.0 ppm, (iii) Chromatogram deconvolution
135 using the local minimum search algorithm with a 70% chromatographic threshold, 0.05 min
136 minimum RT range, 5% minimum relative height, 1200 minimum absolute height, a minimum
137 ratio of peak top/edge of 1.2 and a peak duration range of 0.08–5.0, (iv), Isotopic peak grouper
138 with a m/z tolerance of 5.0 ppm, RT tolerance of 0.05 min, maximum charge of 2 and with the
139 most intense isotope set as the representative isotope, (v) Join aligner with a m/z tolerance of 0.009
140 or 10.0 ppm and a weight for of 2, a RT tolerance of 0.15 min and a weight of 1 and with no
141 requirement of charge state or ID and no comparison of isotope pattern, (vi) Peak list row filter
142 with a minimum of 10% of the samples (vii) Gap filling using the same RT and m/z range gap
143 filler algorithm with an m/z tolerance of 0.009 m/z or 11.0 ppm, (viii) Identification of lipids using
144 a custom database search with an m/z tolerance of 0.008 m/z or 8.0 ppm and a RT tolerance of
145 0.25 min. Identification of lipids was based on an in-house library based on LC-MS/MS data on
146 retention time and mass spectra. The identification was done with a custom data base, with
147 identification levels 1 and 2, *i.e.*, based on authentic standard compounds (level 1) or based on
148 MS/MS identification (level 2).

149 Quantification of lipids was performed using a 7-point internal calibration curve (0.1-5 µg/mL)
150 using the following lipid-class specific authentic standards: using 1-hexadecyl-2-(9Z-
151 octadecenoyl)-sn-glycero-3-phosphocholine (PC(16:0e/18:1(9Z))), 1-(1Z-octadecenyl)-2-(9Z-
152 octadecenoyl)-sn-glycero-3-phosphocholine (PC(18:0p/18:1(9Z))), 1-stearoyl-2-hydroxy-sn-
153 glycero-3-phosphocholine (LPC(18:0)), 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine
154 (LPC(18:1)), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine (PE(16:0/18:1)), 1-(1Z-
155 octadecenyl)-2-docosaheptaenoyl-sn-glycero-3-phosphocholine (PC(18:0p/22:6)) and 1-stearoyl-
156 2-linoleoyl-sn-glycerol (DG(18:0/18:2)), 1-(9Z-octadecenoyl)-sn-glycero-3-
157 phosphoethanolamine (LPE(18:1)), N-(9Z-octadecenoyl)-sphinganine (Cer(d18:0/18:1(9Z))), 1-
158 hexadecyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine (PE(16:0/18:1)) from Avanti
159 Polar Lipids, 1-Palmitoyl-2-Hydroxy-sn-Glycero-3-Phosphatidylcholine (LPC(16:0)), 1,2,3
160 trihexadecanoylglycerol (TG(16:0/16:0/16:0)), 1,2,3-trioctadecanoylglycerol (TG(18:0/18:0/18:0))
161 and 3β-hydroxy-5-cholestene-3-stearate (ChoE(18:0)), 3β-Hydroxy-5-cholestene-3-linoleate
162 (ChoE(18:2)) from Larodan, were prepared to the following concentration levels: 100, 500, 1000,
163 1500, 2000 and 2500 ng/mL (in CHCl₃:MeOH, 2:1, v/v) including 1250 ng/mL of each internal
164 standard.

165 *Analysis of polar metabolites*

166 40 µl of serum sample was mixed with 90 µl of cold MeOH/H₂O (1:1, v/v) containing the internal
167 standard mixture (Valine-d₈, Glutamic acid-d₅, Succinic acid-d₄, Heptadecanoic acid, Lactic acid-
168 d₃, Citric acid-d₄, 3-Hydroxybutyric acid-d₄, Arginine-d₇, Tryptophan-d₅, Glutamine-d₅, each at
169 at c= 1 µg mL⁻¹ and 1-D₄-CA, 1-D₄-CDCA, 1-D₄-CDCA, 1-D₄-GCA, 1-D₄-GCDCA, 1-D₄-
170 GLCA, 1-D₄-GUDCA, 1-D₄-LCA, 1-D₄-TCA, 1-D₄-UDCA, each at 0.2 1 µg mL⁻¹) for protein
171 precipitation. The tube was vortexed and ultrasonicated for 3 min, followed by centrifugation
172 (10000 rpm, 5 min). After centrifuging, 90 µl of the upper layer of the solution was transferred to
173 the LC vial and evaporated under the nitrogen gas to the dryness. After drying, the sample was
174 reconstituted into 60 µl of MeOH: H₂O (70:30).

175 Analyses were performed on an Agilent 1290 Infinity LC system coupled with 6545 QTOFMS
176 interfaced with a dual jet stream electrospray (dual ESI) ion source (Agilent Technologies; Santa
177 Clara, CA, USA) was used for the analysis. Aliquots of 10 μ L of samples were injected into the
178 Acquity UPLC BEH C18 2.1 mm \times 100 mm, 1.7- μ m column (Waters Corporation, Wexford,
179 Ireland), fitted with a C18 precolumn (Waters Corporation, Wexford, Ireland). The mobile phases
180 consisted of (A) 2 mM NH₄Ac in H₂O: MeOH (7:3) and (B) 2 mM NH₄Ac in MeOH. The flow
181 rate was set at 0.4 mLmin⁻¹ with the elution gradient as follows: 0-1.5 min, mobile phase B was
182 increased from 5% to 30%; 1.5-4.5 min, mobile phase B increased to 70%; 4.5-7.5 min, mobile
183 phase B increased to 100% and held for 5.5 min. A post-time of 5 min was used to regain the initial
184 conditions for the next analysis. The total run time per sample was 20 min. The dual ESI ionization
185 source was settings were as follows: capillary voltage was 4.5 kV, nozzle voltage 1500 V, N₂
186 pressure in the nebulized was 21 psi and the N₂ flow rate and temperature as sheath gas was 11
187 Lmin⁻¹ and 379 °C, respectively. In order to obtain accurate mass spectra in MS scan, the m/z
188 range was set to 100-1700 in negative ion mode. MassHunter B.06.01 software (Agilent
189 Technologies; Santa Clara, CA, USA) was used for all data acquisition.

190 MS data processing was performed using same parameters as in lipidomic analysis.

191 Quantitation was done using 6-point calibration (PFOA c= 3.75-120 ng/mL, bile acids c= 20-640
192 ng/mL, polar metabolites c=0.1 to 80 μ g/mL). Quantification of other bile acids was done using
193 the following compounds: chenodeoxycholic acid (CDCA), cholic acid (CA), deoxycholic acid
194 (DCA), glycochenodeoxycholic acid (GCDCA), glycocholic acid (GCA), glycodehydrocholic
195 acid (GDCA), glycodeoxycholic acid (GDCA), glycohyocholic acid (GHCA),
196 glycohyodeoxycholic acid (GHDCA), glycolitocholic acid (GLCA), glycoursodeoxycholic acid
197 (GUDCA), hyocholic acid (HCA), hyodeoxycholic acid (HDCA), lithocholic acid (LCA), alpha-
198 muricholic acid (α MCA), tauro-alpha-muricholic acid (T- α -MCA), tauro-beta-muricholic acid(T-
199 β -MCA), taurochenodeoxycholic acid (TCDCa), taurocholic acid (TCA), taurodehydrocholic
200 acid (THCA), taurodeoxycholic acid (TDCA), taurohyodeoxycholic acid (THDCA),

201 taurochenodeoxycholic acid (TLCA), tauro-omega-muricholic acid (T ω MCA) and tauroursodeoxycholic
202 acid (TDCA) and polar metabolites was done using alanine, citric acid, fumaric acid, glutamic
203 acid, glycine, lactic acid, malic acid, 2-hydroxybutyric acid, 3-hydroxybutyric acid, linoleic acid,
204 oleic acid, palmitic acid, stearic acid, cholesterol, fructose, glutamine, indole-3-propionic acid,
205 isoleucine, leucine, proline, succinic acid, valine, asparagine, aspartic acid, arachidonic acid,
206 glycerol-3-phosphate, lysine, methionine, ornithine, phenylalanine, serine and threonine.

207 *QC/QA*

208 Quality control was accomplished both for lipidomics, polar metabolites and PFAS analysis by
209 including blanks, pure standard samples, extracted standard samples, pooled quality control
210 samples and standard reference plasma samples (NIST SRM 1950). The pooled sample were
211 prepared by taking an aliquot (10 μ l) of each extract, separately for lipidomic and polar metabolite
212 methods, then pooling them, and aliquoting the pool into separate vials. In lipidomic and
213 metabolomic analyses, lipids that had >30% RSD in the pooled QC samples (an equal aliquot of
214 each sample pooled together) or that were present at high concentrations in the extracted blank
215 samples (ratio between samples to blanks < 5) were excluded from the data analyses.

216 **Statistical analysis**

217 *Data pre-processing and clustering*

218 In this study, all data analyses were conducted using the R statistical programming language
219 (version 4.1.2) (<https://www.r-project.org/>). The exposure datasets were pre-processed by log2
220 transformation and scaling to zero mean and unit variance (auto-scaled). For contaminant exposure
221 analyses, individual contaminant and cluster-level analyses were performed. To cluster the
222 contaminant data, we utilized the ‘*mclust*’ R package (version 5.4.10) for model-based clustering,
223 selecting the model type and the number of clusters based on the highest Bayesian Information
224 Criterion (BIC). To better understand the impact of exposure, we also incorporated lipidomics and

225 metabolomics data from our previous study (Hyotylainen et al. 2023), which included eight lipid
226 clusters (LCs) and twelve polar metabolite clusters (PCs), along with their individual features.

227 *Demographic data and covariates*

228 In terms of demographic data and covariates, the median age at the time of diagnosis for subjects
229 who later developed autoimmune diseases was 15 years. We obtained information on birthweight,
230 maternal age, gestational age, and BMI from the questionnaire. Additionally, we utilized
231 birthweight and gestational age to calculate birthweight for gestational age (BWGA) Z-score,
232 utilizing internationally validated infant growth charts developed by Fenton (Chou et al. 2020;
233 Fenton and Kim 2013).

234 *Correlation and partial correlation analysis*

235 Pairwise Spearman's correlation between contaminants, lipid clusters (LCs), Polar metabolite
236 clusters (PCs) and demographic variables (Z-score, Maternal age, BMI) was calculated and
237 visualized using ‘*corrplot*’ R package (version 0.92). Two correlation plots were generated
238 separately for control and cases. The correlation between variables visualised in the form of a
239 matrix plot refers to positive and negative correlations and the strength of the association is referred
240 to by the size of the dot or filled circles.

241 The Debiased Sparse Partial Correlation algorithm (DSPC) (Basu et al. 2017) was used to estimate
242 partial correlation networks and visualized in the form of a chord diagram using ‘*circlize*’, R
243 package (version 0.4.15) with edge ranges between ± 0.14 to 1.0 and showing only correlations
244 across contaminants, LCs, PCs and demographic variables.

245 *Univariate statistical analysis*

246 To understand the impact of contaminant exposure levels on cord serum metabolome, the subjects
247 were assigned to four quartiles based on the exposure levels. A two-way analysis of variance
248 (ANOVA) test was performed followed by post-hoc Tukey’s test by using quartiles (Q1 to Q4)

249 and subjects (cases and control) as factor variables. ANOVA test helps to identify any significant
250 changes in the lipid or metabolite clusters and post-hoc Tukey's test helps to identify the specific
251 quartiles between which significant changes are observed.

252 *Regression and classification analysis*

253 Predictive logistic ridge regression (LRR) was performed to investigate the impact of individual
254 contaminants on the stratification of autoimmune cases and controls. We have adapted the L2
255 regularization strategy to avoid multicollinearity among highly correlated predictors. Regularized
256 regression modelling was performed using the '*glmnet*' package in R (version 4.1-4). The hyper-
257 parameter λ_{minimum} was determined by 10-fold cross-validation using the '*cv.glmnet*' function from
258 '*glmnet*'. The models were adjusted for Z-score, Maternal age and BMI. The accuracy of
259 prediction was determined by AUCs, where the mean AUC of the model was estimated by
260 bootstrapping, by resampling the exposure dataset into training (80%) and testing (20%) 10,000
261 times. All LRR models with a threshold of $\text{AUC} > 0.60$ were considered. Downsampling was
262 performed to address the class imbalance problem (cases, $n=62$, controls, $n >62$). The '*caret*'
263 package (version 4.1.3) was used for the partition of data and the best models (based on mean
264 AUCs) were assessed using Receiver Operating Characteristic (ROC) curves using the '*ROCR*'
265 package. Additionally, we have performed a stepwise recursive feature elimination scheme to
266 identify the minimum number of predictors that are needed to maximize the outcome.

267 To investigate the effect of contaminant exposure on the cord blood metabolome, we employed
268 linear regression with L2 regularization (LR), using individual contaminant concentrations as
269 predictors and the concentrations of significantly altered cord blood lipid or polar metabolites (and
270 their cluster) as the response variable. The hyper-parameter λ_{minimum} , which corresponds to the
271 minimum cross-validation error, was selected through 10-fold cross-validation. We partitioned the
272 data and performed resampling (10,000 iterations) as described earlier. The mean R square was
273 used to estimate the accuracy of prediction and the significant impact of contaminant exposure on
274 the cord blood metabolome.

275 Additionally, we determined the ranks of the predictors using LR and LRR modelling. For the
276 LRR models, the ranks of the predictors were estimated based on the unit absolute differences in
277 the odds ratio, while for the LR models, the ranks were based on the ridge coefficients normalized
278 with the maximum value.

279 *Pathway analysis*

280 Pathway enrichment analysis comparing cases versus controls for Deoxynivalenol (DON) impact
281 polar metabolites was performed using the MetaboAnalyst 5.0 web platform with the Functional
282 Analysis (MS Peaks) module (Pang et al. 2022). The input data for the pathway analysis consisted
283 of complete high-resolution LC-MS spectral peak data obtained in negative ionization mode with
284 a mass tolerance of 10 ppm. Linear regression analysis was performed to estimate the association
285 between DON and polar metabolites while adjusting for Z-score, Maternal age, and BMI. The
286 whole input peak list with FDR-corrected p-values and T-score was used for the pathway analysis.
287 Overrepresented pathways were estimated against the background human scale metabolic model
288 MNF (from MetaboAnalyst Mummichog package) and Kyoto Encyclopedia of Genes and
289 Genomes (KEGG) pathways for Homo sapiens to determine the relative significance of the
290 identified pathways (Li et al. 2020). The MetaboAnalyst 5.0 metabolomics pathway analysis
291 (MetPA) tool(Xia and Wishart 2010) was used to calculate the Pathway Impact Scores (Chong et
292 al. 2018; Pang et al. 2022).

293 **Results**

294 **Metabolomic analysis of the cord blood**

295 **Fig. 1** summarizes the integration of exposomics and metabolomics workflows in the ABIS cohort.
296 Cord serum samples were analyzed for a total of 545 lipids and 3417 polar metabolites, which
297 were further grouped into 8 lipid clusters and 12 polar metabolite clusters, respectively. We
298 previously found significant associations between the metabolite clusters and demographic

299 variables or clinical parameters such as gestational age, maternal age, and birth weight
300 (Hyotylainen et al. 2023). To account for these associations, we used the Z-score as calculated
301 from birth weight, gestational age, and maternal BMI as covariates in our analysis.

302 **Levels of contaminants in the cord blood**

303 A total of 20 contaminants, including several PFAS compounds, were detected in cord blood
304 samples from both control and case groups (**Table S1**). Differences ($p < 0.05$) in concentration
305 levels between control and case groups were observed for Perfluorooctanoic acid Branched 2,
306 Environmental Contaminant 1, Perfluorooctanoic acid Linear 1, Perfluorooctanoic acid Linear 2
307 and Methylparaben (**Fig. 2**). At the individual disease level, Environmental Contaminant 1,
308 Perfluorooctanoic acid Linear 2 and Perfluorooctanoic acid Branched 2 showed differences
309 ($p < 0.05$) in concentration levels between control and individual disease groups (**Fig. S1**). The
310 contaminants were reduced to four clusters (CC1-CC4) consisting of eight contaminants, including
311 Bisphenol S, Deoxynivalenol, Monobutyl phthalate, and α -Zearalanol in CC1; Ethylparaben,
312 Methylparaben, and Propylparaben in CC2; Perfluorohexanesulfonic acid (PFHxS) and
313 Perfluorohexanesulfonic acid Branched (PFHxSBr) in CC3; and seven PFAS and their fragments
314 as part of CC4 (**Table S1**).

315 **Exposure level of contaminants as a predictor for immune-mediated diseases**

316 We employed predictive logistic ridge regression (LRR) models to stratify controls and cases
317 based on their contaminant concentrations. The models were fitted using all predictors or by using
318 the stepwise recursive feature elimination (RFE) method. The mean area under the curve (AUC)
319 values for the models were 0.65 (95% CI 0.63-0.67) when using all predictors and 0.67 (95% CI
320 0.66-0.68) when using the stepwise RFE method (**Fig. S2**). Our results showed that the
321 contaminant concentration levels have a modest potential to differentiate controls from
322 autoimmune diseases, as indicated by the mean AUC values (**Fig. S2**). The ranks of individual

323 contaminants (predictors) for separating controls and cases were estimated based on the unit
324 absolute difference in odds ratios (**Fig. S2A**).

325 **Associations between contaminants and cord serum metabolic profiles**

326 We found significant associations between contaminants and cord serum metabolic profiles (**Fig.**
327 **3**). Specifically, more associations were observed between PFAS exposures and metabolic profiles
328 in cases than in controls. Maternal age was positively associated with metabolite cluster PC1 in
329 cases but not in controls (**Fig. 3**). We also performed partial correlation network analysis to identify
330 non-spurious associations and **Fig. 4** shows the marked associations between contaminants and
331 cord serum metabolic profiles along with demographic variables. In the case group (**Fig. 4B**), the
332 covariates Z-score, maternal age, and BMI showed a stronger association with exposure and cord
333 serum metabolic profiles compared to the control group (**Fig. 4A**). The mycotoxins including
334 deoxynivalenol were found to be associated with PC2 (phosphatidylcholines) and PC10
335 (unknowns), while a-zearalanol was associated with PC1 (lysophosphatidylcholines,
336 sphingomyelins, and ceramides) (**Fig. 4**).

337 **Impact of contaminant exposure on cord serum metabolites associated with immune-** 338 **mediated diseases**

339 The samples were stratified into quartiles based on their level of exposure to contaminants, and
340 the impact of exposure on metabolite levels was assessed at both individual contaminant levels
341 and cluster levels (CC1-CC4) (**Tables S2-S5**). The polar metabolite clusters displayed more
342 significant mean differences between the highest (Q4) and lowest (Q1) quartiles, as shown in
343 **Table S4-S5**. In CC1, significant mean differences between Q4 and Q1 were observed for LC3,
344 LC4, and LC7 at the lipid cluster level (**Table S3**). In CC3, which includes
345 perfluorohexanesulfonic acid (PFHxS) and branched (PFHxSBr), significant mean differences
346 between the highest and lowest quartiles were observed for LC5 and LC6 (**Table S3** and **Fig. 5H**).

347 Linear ridge regression (LR) was performed to determine the quantitative effect of contaminant
348 concentration levels on cord serum metabolic profiles. The results showed that polar metabolites
349 in cord serum were more highly impacted by contaminant exposure than lipid levels. Specifically,
350 six polar metabolite clusters, PC2 ($R^2 = 0.72$), PC6 ($R^2 = 0.53$), PC4 ($R^2 = 0.52$), PC1 ($R^2 = 0.48$),
351 PC10 ($R^2 = 0.48$), and PC11 ($R^2 = 0.32$), showed significant associations with exposure levels
352 (**Fig. 5** and **Fig. S3**). At the individual metabolite level, amino acids such as tryptophan (**Fig. 5C**),
353 Serine of PC2, and 3-Chlorothiopheno [2,3-b]thiophene-2-carbonyl chloride of PC11 showed a
354 significant impact (**Fig. 5F**). According to the ranks of the predictors (contaminants),
355 deoxynivalenol (DON) and Bisphenol S were the top linear predictors of cord serum metabolites
356 and clusters PC2 and PC11 (**Fig. 5A-F**).

357 Although the contaminants from clusters CC1 and CC3 showed a significant association between
358 quartiles (Q4 vs. Q1) and lipid cluster levels LC3, LC4, LC5, LC6, and LC7, their strength of
359 association based on LR models was comparatively weaker (**Fig. 5G-I** and **Fig. S3**). For example,
360 the lipid cluster LC6, which mainly comprises triglycerides containing monounsaturated fatty acid
361 (MUFA) and polyunsaturated fatty acids (PUFA), showed a weaker association ($R^2 = 0.04$) with
362 contaminant exposures (**Fig. 5G-I**).

363 **Pathway analysis of deoxynivalenol exposure**

364 Metabolic pathway enrichment analysis was performed to evaluate the impact of DON on polar
365 metabolites in both control and case groups separately. DON was found to be the top predictor that
366 impacted polar metabolite clusters PC2, PC4, PC10, and PC11, as shown in **Fig. 5** and **Fig. S3**.
367 Both Mummichog and GeneSet Enrichment Analysis (GSEA) algorithms were utilized using
368 MetaboAnalyst 5.0 (Li et al. 2020; Pang et al. 2022). Based on the pathways identified by the
369 impact of DON exposure, both control and case groups showed common and specific metabolic
370 pathways, as presented in **Tables S6-S9**.

371 The MFN pathway map revealed that DON exposure was associated with ‘Tyrosine and
372 Tryptophan metabolism’ in the control group but not in cases. Also ‘Glutathione Metabolism’,
373 ‘Alanine and Aspartate Metabolism’, and ‘Glycerophospholipid metabolism’ were found to be
374 associated with exposure to DON in cases, but not in controls (**Fig. 6A** and **6C**; **Tables S6** and
375 **S8**). Similarly, based on the KEGG pathway maps, ‘Aminoacyl-tRNA biosynthesis’ and ‘Glycine,
376 serine, and threonine metabolism’ were common among control and case groups, while several
377 other metabolic pathways were specific to each group (**Fig. 6B** and **6D**, **Tables S7** and **S9**). In
378 summary, the pathway enrichment analysis provided insights into the metabolic pathways affected
379 by DON exposure in both control and case groups. The results highlight the differences in the
380 impacted pathways between the two groups based on the exposure to DON.

381 **Discussion**

382 We performed integrated exposomics and metabolomics to detect the levels of exposure to
383 contaminants and metabolite levels in cord serum. This comprehensive approach allowed us to
384 assess the combined impact of environmental exposures and metabolic profiles on autoimmune
385 diseases in the ABIS cohort. In our previous study we found similarities in metabolic profiles
386 across different autoimmune diseases at birth (Hyotylainen et al. 2023). In order to avoid class
387 imbalance problems, here we pooled all individual diseases together. We detected 20
388 contaminants, encompassing several PFAS compounds, Bisphenol S, and mycotoxins like
389 Deoxynivalenol (DON), in cord blood samples from both control and case groups. Previous
390 studies, including our own, have reported detectable levels of PFAS compounds (McGlinchey et
391 al. 2020; Sinisalu et al. 2020), Bisphenol S exposure (Liu et al. 2017), and the presence of
392 mycotoxins, including Deoxynivalenol (DON), in cord blood samples (Nielsen et al. 2011). These
393 findings provide a backdrop for our investigation into the associations between these contaminants
394 and autoimmune diseases in the ABIS cohort. We were able to demonstrate significant differences
395 in the exposure levels of certain contaminants, such as Perfluorooctanoic acid Branched 2,
396 Environmental Contaminant 1, Perfluorooctanoic acid Linear 1, Perfluorooctanoic acid Linear 2,

397 and Methylparaben, in cord blood between the control and case groups. However, it is important
398 to note that while these differences were statistically significant, the effect sizes were relatively
399 modest. This suggests that while contaminants do play a role in distinguishing between controls
400 and autoimmune diseases, they are unlikely to be the sole risk factors. Various factors including
401 genetics, environmental triggers, and lifestyle factors, and their mutual interactions, contribute to
402 the development of autoimmune diseases (Ellis et al. 2014; Oresic et al. 2013; Oresic et al. 2008;
403 Rewers and Ludvigsson 2016; Sen et al. 2019; Sen et al. 2020; Sinisalu et al. 2020; Vermeulen et
404 al. 2020; Virolainen et al. 2023).

405 Our study revealed differences in exposure and metabolite profiles between individuals who later
406 developed autoimmune diseases and controls, particularly in relation to Z-score, mothers' age, and
407 BMI. This suggests that there may be differences in maternal factors between the two groups even
408 at birth. We also observed that high levels of exposure to environmental contaminants were
409 associated with changes in amino acid and free fatty acid profiles in the cord blood metabolome.
410 Although we previously found a significant impact on lipid profiles, particularly triacylglycerols,
411 the strength of association is weaker compared to the effect on polar metabolites (Hyotylainen et
412 al. 2023). Among the 20 contaminants measured in our study, DON, Bisphenol S, and some
413 branched PFAS compounds are the primary predictors of changes in cord serum metabolic
414 profiles. While the associations between PFAS exposure and their marked effect on metabolism
415 leading to autoimmune diseases have been well documented in previous studies (Ehrlich et al.
416 2023; McGlinchey et al. 2020; Rudzanova et al. 2023; Sinisalu et al. 2020), the exposure to DON
417 and BPS and their impact on autoimmune diseases is less studied.

418 While our study detected Bisphenol S (BPS) and not Bisphenol A (BPA), it's noteworthy that BPA,
419 a common chemical found in plastics, has been associated with alterations in amino acid
420 metabolism (Wang et al. 2018). BPA has been linked to changes in phenylalanine, tryptophan,
421 tyrosine, lysine, and arginine metabolism, with a particular impact on female infants (Khan et al.
422 2017). In the case of BPS, it was shown to have sex- and diet-dependent effects on the development

423 of type 1 diabetes (T1D) in non-obese diabetic (NOD) mice. Female mice exposed to BPS on a
424 soy-based diet exhibited delayed T1D development, while males showed increased insulin
425 resistance (Xu et al. 2019). These findings suggest that both BPA and BPS can influence
426 metabolism and immune responses, potentially contributing to autoimmune diseases like T1D,
427 although there is less evidence regarding the effect of BPS in humans.

428 Deoxynivalenol (DON) exposure in pregnant women has been reported in various studies. In the
429 UK, pregnant women from diverse backgrounds showed detectable urinary DON levels, with
430 South Asian women having higher exposure, primarily from bread consumption (Hepworth et al.
431 2012). Similarly, in Norway, DON, a common mycotoxin in cereals, was found in various cereal-
432 based foods, potentially affecting the immune system, particularly in infants and young children
433 (Sundheim et al. 2017). In pregnant Egyptian women, DON co-occurred with other mycotoxins,
434 raising concerns about maternal and fetal health (Piekkola et al. 2012).

435 These findings emphasize the importance of assessing DON exposure in pregnant women and its
436 potential health implications. DON exposure, prevalent in grains, adversely affects the immune
437 system in both humans and animals and has been linked to alterations in gut microbiota (Liao et
438 al. 2018). This immunotoxicity induced by DON involves mechanisms such as MAPK activation,
439 ER stress, and mitochondrial signaling pathways (Liao et al. 2018).

440 To delve deeper into the potential mechanisms underlying these associations, we conducted
441 pathway analysis of DON exposure on polar metabolites within both control and case groups. This
442 analysis revealed that DON had distinct impacts on metabolic pathways in these groups. In the
443 control group, DON exposure was associated with alterations in 'Tyrosine and Tryptophan
444 metabolism,' indicating potential effects on amino acid pathways. Conversely, the case group
445 showed associations between DON exposure and 'Glutathione Metabolism,' 'Alanine and
446 Aspartate Metabolism,' and 'Glycerophospholipid metabolism,' suggesting disruptions in
447 antioxidant defense systems and lipid metabolism. These findings align with previous research
448 indicating that DON can induce oxidative stress by reducing antioxidant enzyme activity and

449 enhancing lipid peroxidation (Mishra et al. 2014). The marked association between DON and
450 phosphatidylcholines in our study suggests a potential link between mycotoxin exposure and
451 alterations in lipid metabolism, particularly in the context of phosphatidylcholines. This finding is
452 noteworthy, as specific phosphatidylcholines were previously identified as persistently down-
453 regulated in children who later progressed to islet autoimmunity (Johnson et al. 2019) and clinical
454 type 1 diabetes (T1D) (Oresic et al. 2008). Thus, the oxidative stress response and its impact on
455 lipid metabolism, triggered by DON exposure, may play a pivotal role in the pathogenesis of
456 autoimmune diseases, warranting further investigation.

457 These differential effects of DON exposure on metabolic pathways between control and case
458 groups highlight the intricate relationship between environmental exposures, metabolism, and
459 immune dysregulation in the context of autoimmune diseases. While our study contributes to our
460 understanding of the metabolic consequences of DON exposure, it's essential to consider these
461 findings within the broader context of various factors, including genetics, environmental triggers,
462 and lifestyle factors, which collectively contribute to the development of autoimmune diseases.
463 Understanding these effects is crucial when assessing DON exposure during pregnancy and its
464 potential health consequences. In this study, the median age of diagnosis of autoimmune diseases
465 was higher compared to previous studies in genetically high-risk cohorts (Oresic et al. 2013; Oresic
466 et al. 2008; Sen et al. 2019). Despite some common metabolic patterns (Hyotylainen et al. 2023),
467 there were differences and limitations to consider. One important limitation of our study was the
468 small sample size within each disease group, which restricted our analysis. Another limitation of
469 our study was the lack of maternal exposure and longitudinal exposure data at different time points
470 between birth and the onset of autoimmune diseases, which could explain their age-dependent
471 progression.

472 Our previous studies in T1D (McGlinchey et al. 2020) and CD (Sinisalu et al. 2020) cohorts have
473 mainly focus on the associations of PFAS exposure with the disease risk. Here we detected the
474 levels of other contaminants such as Bisphenol S and some mycotoxins including DON and a-

475 Zearalanol, which potentially show the differences in exposures. Mycotoxins are common
476 contaminants of cereals and grains, and exposure to them is also associated with autoimmune
477 disorders (Gayathri et al. 2018; Kraft et al. 2021; Liao et al. 2018; Rotter et al. 1996). This
478 emphasizes the need for caution and control over mycotoxin exposure, particularly during
479 pregnancy and critical developmental stages.

480 Altogether, our results show that high prenatal exposure to environmental contaminants associated
481 with altered cord serum metabolite levels and may result in the progression of autoimmune
482 diseases in the ABIS cohort. Other factors such as Z-score, maternal age and BMI are associated
483 with contaminant exposure levels. Mechanistic studies are required to elucidate pathways of
484 disease progression upon exposure.

485 **Author contributions**

486 Bagavathy Shanmugam Karthikeyan: Formal analysis, Software, Visualization, Writing - Original
487 Draft; Tuulia Hyötyläinen: Conceptualization, methodology, formal analysis, investigation,
488 writing – original draft, supervision, project administration, funding acquisition; Tannaz
489 Ghaffarzadegan: Writing – review and editing, methodology; Eric W. Triplett: Conceptualization,
490 writing – review and editing; Matej Orešič: Conceptualization, writing – original draft, formal
491 analysis, supervision; Johnny Ludvigsson: Conceptualization, writing – review and editing,
492 funding acquisition, design and management of the ABIS cohort study.

493 **Acknowledgements**

494 BSK thanks Partho Sen for his guidance in Methods and Alex Dickens for his insightful
495 discussions. The authors thank Dirk Repsilber for his support in using the UCS-1 server from
496 Örebro University for computations. This work was supported by the Swedish Research Council
497 [grant number 2020-03674; to TH], Formas [grant number 2019-00869; to TH], and by the
498 “Inflammation in human early life: targeting impacts on life-course health” (INITIALISE)

499 consortium funded by the Horizon Europe Program of the European Union under Grant Agreement
500 101094099 (to T.H., E.W.T., M.O., and J.L.). The ABIS cohort study (JL) was supported by
501 Barndiabetesfonden (Swedish Child Diabetes Foundation), the Swedish Council for Working Life
502 and Social Research [grant numbers FAS2004-1775 and FAS2004–1775], Swedish Research
503 Council [Grant/Award Numbers: K2005-72 × -11242-11A and K2008-69 × -20826-01-4, K2008-
504 69 × -20826-01-4], Östgöta Brandstodsbolag, Medical Research Council of Southeast Sweden
505 (FORSS), JDRF Wallenberg Foundation [Grant/Award Number: K 98-99D-12813-01A], Joanna
506 Coccozza Foundation and ALF-and LfoU grants from Region Östergötland and Linköping
507 University, Sweden.

508 **Competing interests**

509 The authors have no competing interests to declare.

510 **Data accessibility**

511 Data are available upon reasonable request after ethical approval and an appropriate
512 institutional collaboration agreement. These data are not available to access in a repository owing
513 to concern that the identity of patients might be revealed inadvertently.

514 **References**

- 515
516 Basu, S.; Duren, W.; Evans, C.R.; Burant, C.F.; Michailidis, G.; Karnovsky, A. Sparse network
517 modeling and metscape-based visualization methods for the analysis of large-scale
518 metabolomics data. *Bioinformatics* 2017;33:1545-1553
- 519 Belteky, M.; Milletich, P.L.; Ahrens, A.P.; Triplett, E.W.; Ludvigsson, J. Infant gut microbiome
520 composition correlated with type 1 diabetes acquisition in the general population: the
521 ABIS study. *Diabetologia* 2023;66:1116-1128
- 522 Berhan, Y.; Waernbaum, I.; Lind, T.; Mollsten, A.; Dahlquist, G.; Swedish Childhood Diabetes
523 Study, G. Thirty years of prospective nationwide incidence of childhood type 1 diabetes:
524 the accelerating increase by time tends to level off in Sweden. *Diabetes* 2011;60:577-581
- 525 Buhimschi, I.A.; Buhimschi, C.S. Proteomics/diagnosis of chorioamnionitis and of relationships
526 with the fetal exposome. *Semin Fetal Neonatal Med* 2012;17:36-45
- 527 Carstensen, B.; Ronn, P.F.; Jorgensen, M.E. Prevalence, incidence and mortality of type 1 and
528 type 2 diabetes in Denmark 1996-2016. *BMJ Open Diabetes Res Care* 2020;8

- 529 Chew, N.W.S.; Ng, C.H.; Tan, D.J.H.; Kong, G.; Lin, C.; Chin, Y.H.; Lim, W.H.; Huang, D.Q.;
530 Quek, J.; Fu, C.E.; Xiao, J.; Syn, N.; Foo, R.; Khoo, C.M.; Wang, J.W.; Dimitriadis,
531 G.K.; Young, D.Y.; Siddiqui, M.S.; Lam, C.S.P.; Wang, Y.; Figtree, G.A.; Chan, M.Y.;
532 Cummings, D.E.; Nouredin, M.; Wong, V.W.; Ma, R.C.W.; Mantzoros, C.S.; Sanyal,
533 A.; Muthiah, M.D. The global burden of metabolic disease: Data from 2000 to 2019. *Cell*
534 *Metab* 2023;35:414-428 e413
- 535 Chong, J.; Soufan, O.; Li, C.; Caraus, I.; Li, S.; Bourque, G.; Wishart, D.S.; Xia, J.
536 *MetaboAnalyst 4.0: towards more transparent and integrative metabolomics analysis.*
537 *Nucleic Acids Res* 2018;46:W486-W494
- 538 Chou, J.H.; Roumiantsev, S.; Singh, R. *PediTools Electronic Growth Chart Calculators:*
539 *Applications in Clinical Care, Research, and Quality Improvement. J Med Internet Res*
540 2020;22:e16204
- 541 Cui, Y.; Balshaw, D.M.; Kwok, R.K.; Thompson, C.L.; Collman, G.W.; Birnbaum, L.S. The
542 *Exposome: Embracing the Complexity for Discovery in Environmental Health. Environ*
543 *Health Perspect* 2016;124:A137-140
- 544 Diseases, G.B.D.; Injuries, C. Global burden of 369 diseases and injuries in 204 countries and
545 territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study
546 2019. *Lancet* 2020;396:1204-1222
- 547 Eaton, W.W.; Rose, N.R.; Kalaydjian, A.; Pedersen, M.G.; Mortensen, P.B. Epidemiology of
548 autoimmune diseases in Denmark. *J Autoimmun* 2007;29:1-9
- 549 Ehrlich, V.; Bil, W.; Vandebriel, R.; Granum, B.; Luijten, M.; Lindeman, B.; Grandjean, P.;
550 Kaiser, A.M.; Hauzenberger, I.; Hartmann, C.; Gundacker, C.; Uhl, M. Consideration of
551 pathways for immunotoxicity of per- and polyfluoroalkyl substances (PFAS). *Environ*
552 *Health* 2023;22:19
- 553 Ellis, J.A.; Kemp, A.S.; Ponsonby, A.L. Gene-environment interaction in autoimmune disease.
554 *Expert Rev Mol Med* 2014;16:e4
- 555 Fenton, T.R.; Kim, J.H. A systematic review and meta-analysis to revise the Fenton growth chart
556 for preterm infants. *BMC Pediatr* 2013;13:59
- 557 Filimoniuk, A.; Daniluk, U.; Samczuk, P.; Wasilewska, N.; Jakimiec, P.; Kucharska, M.;
558 Lebensztejn, D.M.; Ciborowski, M. Metabolomic profiling in children with inflammatory
559 bowel disease. *Adv Med Sci* 2020;65:65-70
- 560 Gayathri, L.; Karthikeyan, B.S.; Rajalakshmi, M.; Dhanasekaran, D.; Li, A.P.; Akbarsha, M.A.
561 *Metabolism-dependent cytotoxicity of citrinin and ochratoxin A alone and in*
562 *combination as assessed adopting integrated discrete multiple organ co-culture (IdMOC).*
563 *Toxicol In Vitro* 2018;46:166-177
- 564 Harjutsalo, V.; Sund, R.; Knip, M.; Groop, P.H. Incidence of type 1 diabetes in Finland. *JAMA*
565 2013;310:427-428
- 566 Hepworth, S.J.; Hardie, L.J.; Fraser, L.K.; Burley, V.J.; Mijal, R.S.; Wild, C.P.; Azad, R.;
567 McKinney, P.A.; Turner, P.C. Deoxynivalenol exposure assessment in a cohort of
568 pregnant women from Bradford, UK. *Food Addit Contam Part A Chem Anal Control*
569 *Expo Risk Assess* 2012;29:269-276

- 570 Hyotylainen, T.; Karthikeyan, B.S.; Ghaffarzagdegan, T.; Triplett, E.W.; Oresic, M.; Ludvigsson,
571 J. Cord serum metabolic signatures of future progression to immune-mediated diseases.
572 *iScience* 2023;26:106268
- 573 Ilonen, J.; Kiviniemi, M.; Lempainen, J.; Simell, O.; Toppari, J.; Veijola, R.; Knip, M.; Finnish
574 Pediatric Diabetes, R. Genetic susceptibility to type 1 diabetes in childhood - estimation
575 of HLA class II associated disease risk and class II effect in various phases of islet
576 autoimmunity. *Pediatr Diabetes* 2016;17 Suppl 22:8-16
- 577 Johnson, R.K.; Tamura, R.; Frank, N.; Uusitalo, U.; Yang, J.; Niinisto, S.; Andren Aronsson, C.;
578 Ziegler, A.G.; Hagopian, W.; Rewers, M.; Toppari, J.; Akolkar, B.; Krischer, J.;
579 Virtanen, S.M.; Norris, J.M.; Group, T.S. Maternal food consumption during late
580 pregnancy and offspring risk of islet autoimmunity and type 1 diabetes. *Diabetologia*
581 2021;64:1604-1612
- 582 Johnson, R.K.; Vanderlinden, L.; DeFelice, B.C.; Kechris, K.; Uusitalo, U.; Fiehn, O.; Sontag,
583 M.; Crume, T.; Beyerlein, A.; Lernmark, A.; Toppari, J.; Ziegler, A.G.; She, J.X.;
584 Hagopian, W.; Rewers, M.; Akolkar, B.; Krischer, J.; Virtanen, S.M.; Norris, J.M.;
585 Group, T.S. Metabolite-related dietary patterns and the development of islet
586 autoimmunity. *Sci Rep* 2019;9:14819
- 587 Karthikeyan, B.S.; Ravichandran, J.; Aparna, S.R.; Samal, A. ExHuMIId: A curated resource and
588 analysis of Exposome of Human Milk across India. *Chemosphere* 2021;271:129583
- 589 Katsarou, A.; Gudbjornsdottir, S.; Rawshani, A.; Dabelea, D.; Bonifacio, E.; Anderson, B.J.;
590 Jacobsen, L.M.; Schatz, D.A.; Lernmark, A. Type 1 diabetes mellitus. *Nat Rev Dis*
591 *Primers* 2017;3:17016
- 592 Khan, A.; Park, H.; Lee, H.A.; Park, B.; Gwak, H.S.; Lee, H.R.; Jee, S.H.; Park, Y.H. Elevated
593 Metabolites of Steroidogenesis and Amino Acid Metabolism in Preadolescent Female
594 Children With High Urinary Bisphenol A Levels: A High-Resolution Metabolomics
595 Study. *Toxicol Sci* 2017;160:371-385
- 596 Khan, M.F.; Wang, H. Environmental Exposures and Autoimmune Diseases: Contribution of
597 Gut Microbiome. *Front Immunol* 2019;10:3094
- 598 Kindgren, E.; Ahrens, A.P.; Triplett, E.W.; Ludvigsson, J. Infant gut microbiota and
599 environment associate with juvenile idiopathic arthritis many years prior to disease onset,
600 especially in genetically vulnerable children. *EBioMedicine* 2023;93:104654
- 601 Kostic, A.D.; Gevers, D.; Siljander, H.; Vatanen, T.; Hyotylainen, T.; Hamalainen, A.M.; Peet,
602 A.; Tillmann, V.; Poho, P.; Mattila, I.; Lahdesmaki, H.; Franzosa, E.A.; Vaarala, O.; de
603 Goffau, M.; Harmsen, H.; Ilonen, J.; Virtanen, S.M.; Clish, C.B.; Oresic, M.;
604 Huttenhower, C.; Knip, M.; Group, D.S.; Xavier, R.J. The dynamics of the human infant
605 gut microbiome in development and in progression toward type 1 diabetes. *Cell Host*
606 *Microbe* 2015;17:260-273
- 607 Kraft, S.; Buchenauer, L.; Polte, T. Mold, Mycotoxins and a Dysregulated Immune System: A
608 Combination of Concern? *Int J Mol Sci* 2021;22
- 609 Landrigan, P.J.; Goldman, L.R. Children's vulnerability to toxic chemicals: a challenge and
610 opportunity to strengthen health and environmental policy. *Health Aff (Millwood)*
611 2011;30:842-850

- 612 Landrigan, P.J.; Sly, J.L.; Ruchirawat, M.; Silva, E.R.; Huo, X.; Diaz-Barriga, F.; Zar, H.J.;
613 King, M.; Ha, E.H.; Asante, K.A.; Ahanchian, H.; Sly, P.D. Health Consequences of
614 Environmental Exposures: Changing Global Patterns of Exposure and Disease. *Ann Glob*
615 *Health* 2016;82:10-19
- 616 Li, S.; Cirillo, P.; Hu, X.; Tran, V.; Krigbaum, N.; Yu, S.; Jones, D.P.; Cohn, B. Understanding
617 mixed environmental exposures using metabolomics via a hierarchical community
618 network model in a cohort of California women in 1960's. *Reprod Toxicol* 2020;92:57-65
- 619 Liao, Y.; Peng, Z.; Chen, L.; Nussler, A.K.; Liu, L.; Yang, W. Deoxynivalenol, gut microbiota
620 and immunotoxicity: A potential approach? *Food Chem Toxicol* 2018;112:342-354
- 621 Liu, J.; Li, J.; Wu, Y.; Zhao, Y.; Luo, F.; Li, S.; Yang, L.; Moez, E.K.; Dinu, I.; Martin, J.W.
622 Bisphenol A Metabolites and Bisphenol S in Paired Maternal and Cord Serum. *Environ*
623 *Sci Technol* 2017;51:2456-2463
- 624 Ludvigsson, J.; Ludvigsson, M.; Sepa, A. Screening for prediabetes in the general child
625 population: maternal attitude to participation. *Pediatr Diabetes* 2001;2:170-174
- 626 McGlinchey, A.; Sinioja, T.; Lamichhane, S.; Sen, P.; Bodin, J.; Siljander, H.; Dickens, A.M.;
627 Geng, D.; Carlsson, C.; Duberg, D.; Ilonen, J.; Virtanen, S.M.; Dirven, H.; Berntsen,
628 H.F.; Zimmer, K.; Nygaard, U.C.; Oresic, M.; Knip, M.; Hyotylainen, T. Prenatal
629 exposure to perfluoroalkyl substances modulates neonatal serum phospholipids,
630 increasing risk of type 1 diabetes. *Environ Int* 2020;143:105935
- 631 Mishra, S.; Dwivedi, P.D.; Pandey, H.P.; Das, M. Role of oxidative stress in Deoxynivalenol
632 induced toxicity. *Food Chem Toxicol* 2014;72:20-29
- 633 Nielsen, J.K.; Vikstrom, A.C.; Turner, P.; Knudsen, L.E. Deoxynivalenol transport across the
634 human placental barrier. *Food Chem Toxicol* 2011;49:2046-2052
- 635 Nygren, M.; Carstensen, J.; Koch, F.; Ludvigsson, J.; Frostell, A. Experience of a serious life
636 event increases the risk for childhood type 1 diabetes: the ABIS population-based
637 prospective cohort study. *Diabetologia* 2015;58:1188-1197
- 638 Oresic, M.; Gopalacharyulu, P.; Mykkanen, J.; Lietzen, N.; Makinen, M.; Nygren, H.; Simell, S.;
639 Simell, V.; Hyoty, H.; Veijola, R.; Ilonen, J.; Sysi-Aho, M.; Knip, M.; Hyotylainen, T.;
640 Simell, O. Cord serum lipidome in prediction of islet autoimmunity and type 1 diabetes.
641 *Diabetes* 2013;62:3268-3274
- 642 Oresic, M.; Simell, S.; Sysi-Aho, M.; Nanto-Salonen, K.; Seppanen-Laakso, T.; Parikka, V.;
643 Katajamaa, M.; Hekkala, A.; Mattila, I.; Keskinen, P.; Yetukuri, L.; Reinikainen, A.;
644 Lahde, J.; Suortti, T.; Hakalax, J.; Simell, T.; Hyoty, H.; Veijola, R.; Ilonen, J.;
645 Lahesmaa, R.; Knip, M.; Simell, O. Dysregulation of lipid and amino acid metabolism
646 precedes islet autoimmunity in children who later progress to type 1 diabetes. *J Exp Med*
647 2008;205:2975-2984
- 648 Pang, Z.; Zhou, G.; Ewald, J.; Chang, L.; Hacariz, O.; Basu, N.; Xia, J. Using MetaboAnalyst 5.0
649 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of
650 global metabolomics data. *Nat Protoc* 2022;17:1735-1761
- 651 Patterson, C.C.; Dahlquist, G.G.; Gyurus, E.; Green, A.; Soltesz, G.; Group, E.S. Incidence
652 trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases
653 2005-20: a multicentre prospective registration study. *Lancet* 2009;373:2027-2033

- 654 Piekkola, S.; Turner, P.C.; Abdel-Hamid, M.; Ezzat, S.; El-Daly, M.; El-Kafrawy, S.;
655 Savchenko, E.; Poussa, T.; Woo, J.C.; Mykkanen, H.; El-Nezami, H. Characterisation of
656 aflatoxin and deoxynivalenol exposure among pregnant Egyptian women. *Food Addit*
657 *Contam Part A Chem Anal Control Expo Risk Assess* 2012;29:962-971
- 658 Pluskal, T.; Castillo, S.; Villar-Briones, A.; Oresic, M. MZmine 2: modular framework for
659 processing, visualizing, and analyzing mass spectrometry-based molecular profile data.
660 *BMC Bioinformatics* 2010;11:395
- 661 Rewers, M.; Ludvigsson, J. Environmental risk factors for type 1 diabetes. *Lancet*
662 2016;387:2340-2348
- 663 Robinson, O.; Vrijheid, M. The Pregnancy Exposome. *Curr Environ Health Rep* 2015;2:204-213
- 664 Rosenblum, M.D.; Gratz, I.K.; Paw, J.S.; Abbas, A.K. Treating human autoimmunity: current
665 practice and future prospects. *Sci Transl Med* 2012;4:125sr121
- 666 Rotter, B.A.; Prelusky, D.B.; Pestka, J.J. Toxicology of deoxynivalenol (vomitoxin). *J Toxicol*
667 *Environ Health* 1996;48:1-34
- 668 Rudzanova, B.; Vlaanderen, J.; Kalina, J.; Piler, P.; Zvonar, M.; Klanova, J.; Blaha, L.;
669 Adamovsky, O. Impact of PFAS exposure on prevalence of immune-mediated diseases in
670 adults in the Czech Republic. *Environ Res* 2023;229:115969
- 671 Sen, P.; Carlsson, C.; Virtanen, S.M.; Simell, S.; Hyoty, H.; Ilonen, J.; Toppari, J.; Veijola, R.;
672 Hyotylainen, T.; Knip, M.; Oresic, M. Persistent Alterations in Plasma Lipid Profiles
673 Before Introduction of Gluten in the Diet Associated With Progression to Celiac Disease.
674 *Clin Transl Gastroenterol* 2019;10:1-10
- 675 Sen, P.; Dickens, A.M.; Lopez-Bascon, M.A.; Lindeman, T.; Kemppainen, E.; Lamichhane, S.;
676 Ronkko, T.; Ilonen, J.; Toppari, J.; Veijola, R.; Hyoty, H.; Hyotylainen, T.; Knip, M.;
677 Oresic, M. Metabolic alterations in immune cells associate with progression to type 1
678 diabetes. *Diabetologia* 2020;63:1017-1031
- 679 Shaffer, R.M.; Sellers, S.P.; Baker, M.G.; de Buen Kalman, R.; Frostad, J.; Suter, M.K.;
680 Anenberg, S.C.; Balbus, J.; Basu, N.; Bellinger, D.C.; Birnbaum, L.; Brauer, M.; Cohen,
681 A.; Ebi, K.L.; Fuller, R.; Grandjean, P.; Hess, J.J.; Kogevinas, M.; Kumar, P.; Landrigan,
682 P.J.; Lanphear, B.; London, S.J.; Rooney, A.A.; Stanaway, J.D.; Trasande, L.; Walker,
683 K.; Hu, H. Improving and Expanding Estimates of the Global Burden of Disease Due to
684 Environmental Health Risk Factors. *Environ Health Perspect* 2019;127:105001
- 685 Sinisalu, L.; Sen, P.; Salihovic, S.; Virtanen, S.M.; Hyoty, H.; Ilonen, J.; Toppari, J.; Veijola, R.;
686 Oresic, M.; Knip, M.; Hyotylainen, T. Early-life exposure to perfluorinated alkyl
687 substances modulates lipid metabolism in progression to celiac disease. *Environ Res*
688 2020;188:109864
- 689 Sundheim, L.; Lillegaard, I.T.; Faeste, C.K.; Brantsaeter, A.L.; Brodal, G.; Eriksen, G.S.
690 Deoxynivalenol Exposure in Norway, Risk Assessments for Different Human Age
691 Groups. *Toxins (Basel)* 2017;9
- 692 Tincani, A.; Dall'Ara, F.; Lazzaroni, M.G.; Reggia, R.; Andreoli, L. Pregnancy in patients with
693 autoimmune disease: A reality in 2016. *Autoimmun Rev* 2016;15:975-977
- 694 Vatanen, T.; Franzosa, E.A.; Schwager, R.; Tripathi, S.; Arthur, T.D.; Vehik, K.; Lernmark, A.;
695 Hagopian, W.A.; Rewers, M.J.; She, J.X.; Toppari, J.; Ziegler, A.G.; Akolkar, B.;

- 696 Krischer, J.P.; Stewart, C.J.; Ajami, N.J.; Petrosino, J.F.; Gevers, D.; Lahdesmaki, H.;
697 Vlamakis, H.; Huttenhower, C.; Xavier, R.J. The human gut microbiome in early-onset
698 type 1 diabetes from the TEDDY study. *Nature* 2018;562:589-594
- 699 Vermeulen, R.; Schymanski, E.L.; Barabasi, A.L.; Miller, G.W. The exposome and health:
700 Where chemistry meets biology. *Science* 2020;367:392-396
- 701 Virolainen, S.J.; VonHandorf, A.; Viel, K.; Weirauch, M.T.; Kottyan, L.C. Gene-environment
702 interactions and their impact on human health. *Genes Immun* 2023;24:1-11
- 703 Virtanen, S.M.; Nevalainen, J.; Kronberg-Kippila, C.; Ahonen, S.; Tapanainen, H.; Uusitalo, L.;
704 Takkinen, H.M.; Niinisto, S.; Ovaskainen, M.L.; Kenward, M.G.; Veijola, R.; Ilonen, J.;
705 Simell, O.; Knip, M. Food consumption and advanced beta cell autoimmunity in young
706 children with HLA-conferred susceptibility to type 1 diabetes: a nested case-control
707 design. *Am J Clin Nutr* 2012;95:471-478
- 708 Wang, M.; Rang, O.; Liu, F.; Xia, W.; Li, Y.; Zhang, Y.; Lu, S.; Xu, S. A systematic review of
709 metabolomics biomarkers for Bisphenol A exposure. *Metabolomics* 2018;14:45
- 710 Weis, M. Impact of the gut microbiome in cardiovascular and autoimmune diseases. *Clin Sci*
711 (Lond) 2018;132:2387-2389
- 712 Wilson, J.C.; Furlano, R.I.; Jick, S.S.; Meier, C.R. Inflammatory Bowel Disease and the Risk of
713 Autoimmune Diseases. *J Crohns Colitis* 2016;10:186-193
- 714 Xia, J.; Wishart, D.S. MetPA: a web-based metabolomics tool for pathway analysis and
715 visualization. *Bioinformatics* 2010;26:2342-2344
- 716 Xu, J.; Huang, G.; Guo, T.L. Bisphenol S Modulates Type 1 Diabetes Development in Non-
717 Obese Diabetic (NOD) Mice with Diet- and Sex-Related Effects. *Toxics* 2019;7
718
719
720
721

722 **Figure captions**

723 **Fig. 1. Summary of our work, which aimed to investigate how prenatal exposure to**
724 **environmental contaminants alters the cord serum metabolome in the ABIS cohort.** We used
725 metabolomics to determine the levels of exposure to environmental contaminants and metabolites
726 in the cord blood. Our work involved three main stages. Firstly, we examined the levels of
727 exposure and significant differences between control (N = 268) and cases (N = 62). Secondly, we
728 studied the associations of contaminant exposure with cord serum metabolic profiles. Finally, we
729 investigated the impact of contaminant exposure on cord serum metabolites. Overall, our work
730 sheds light on the effects of environmental contaminants on the cord serum metabolome, which
731 may have implications for the future progression of autoimmune diseases.

732 **Fig. 2. Box plots that illustrate the levels of selected contaminants in control and cases.** The
733 violin plots (A-F) on top of the box plots depict the distribution of the selected contaminants (log₂
734 intensities). To test the mean difference between the control and cases, we conducted a Wilcoxon
735 test. The p-values are provided to indicate the significance levels for the mean differences between
736 the two groups for each contaminant (A-F). Specifically, $p < 0.05$ indicates statistical significance,
737 and $p < 0.1$ suggests a trend toward significance. Overall, these results help to identify specific
738 contaminants that may contribute to the altered cord serum metabolome in cases.

739 **Fig. 3. Correlation plots that depict the relationships between contaminant exposure,**
740 **metabolite clusters, and demographic data in controls (A) and cases (B).** We used pairwise
741 Spearman correlation to calculate the correlation coefficients between all cluster variables,
742 contaminants, and demographic variables in the ABIS cohort. Positive and negative correlations
743 are denoted by blue and red colours, respectively. The size of the dot in each cell corresponds to
744 the strength of the pairwise correlation. To improve visualization, we only show correlations
745 between +/- 0.20 to 1.0 in the plots. Overall, these correlation plots provide a comprehensive

746 overview of the complex relationships between environmental contaminants, metabolites, and
747 demographic factors in the ABIS cohort.

748 **Fig. 4. Partial correlation network in the form of a chord diagram that shows the associations**
749 **between contaminant exposure, metabolite clusters, and demographic data in controls (A)**
750 **and cases (B).** To filter out spurious or indirect correlations between variables, we used the
751 Debaised Sparse Partial Correlation (DSPC) algorithm (Basu et al. 2017) to only show direct
752 correlations. We used a conservative cut-off between +/- 0.14 to 1.0 to visualize the correlations
753 and project only correlations across groups (Contaminants, metabolite clusters, and
754 covariates/demographic data). Positive and negative correlations are denoted by blue and red lines,
755 respectively. Overall, this partial correlation network provides a more detailed view of the complex
756 relationships between environmental contaminants, metabolites, and demographic factors in the
757 ABIS cohort.

758 **Fig. 5. Impact of environmental contaminants on cord serum metabolites.** Horizontal bar plots
759 (A, D, G) and (C, F, I) display the ranks of contaminants as predictors of metabolite clusters (PC2,
760 PC11, and LC6) and individual metabolites (Tryptophan, 3-Chlorothiemo [2,3-b]thiophene-2-
761 carbonyl chloride, and TG(16:0/18:2/18:2)), respectively. The potential impact of contaminants
762 on metabolite clusters or individual metabolites is determined by their rank at the top of the bar
763 plot. The ranks are based on their absolute normalized (ridge) regression coefficients. Violin plots
764 (B, E, H) show the levels of metabolites (clusters) associated with levels of exposure to
765 contaminants from contaminants clusters 1 (CC1) and 3 (CC3). The violin plot represents the
766 density of the sample within each quartile, and their distribution is represented using a box plot at
767 the centre. Two-way ANOVA followed by post-hoc Tukey's HSD test was used to compare the
768 mean difference between levels of metabolites (along quartiles).


769 **Fig. 6. Pathway enrichment analysis comparing cases versus controls for Deoxynivalenol**
770 **(DON) impact polar metabolites.** The scatter plots depict the p-values using two different
771 pathway maps: MFN pathway maps on the left panels and KEGG pathway maps on the right

772 panels. The pathway analysis methods Mummichog and GSEA are used on the y-axis and x-axis,
773 respectively, for both control (A, B) and cases (C, D). The size of the circle on each scatter plot
774 represents the pathway impact value. For more detailed information, such as the number of
775 metabolites in the pathways (total number/hits/significant hits) and p-values, please refer to the
776 supplementary information.

777


778

779 **Fig. 1**




780

781 **Fig. 2**




782

785 **Fig. 4**




786

787 **Fig. 5**



788

789 **Fig. 6**



790

791

Prenatal exposure to environmental contaminants is associated with altered cord serum metabolite profiles in future immune-mediated diseases

Supplementary Material




Fig. S1. Box plots that show the levels of selected contaminants in the ABIS cohort at the individual disease levels. The violin plots (A-D) on top of the box plots illustrate the distribution of the selected contaminants (\log_2 intensities). To compare multiple group means, we used the Kruskal-Wallis Test, and for pairwise comparison against the reference (Control), we used the Wilcoxon Test. The p-values are provided to indicate the significance levels for the mean differences between the two groups (control vs. cases) for each contaminant (A-D). Specifically, $p < 0.05$ indicates statistical significance, and $p < 0.1$ suggests a trend toward significance. CD, HT, IBD, JIA, and T1D refer to Celiac disease, Hypothyroidism, Crohn's disease, Juvenile Idiopathic Arthritis and Type 1 Diabetes respectively.




Fig. S2. Classification of controls and immune-mediated diseases using contaminant exposure as predictors. In panel A, the ranks of the predictors (contaminants) obtained from the Logistic ridge regression (LRR) model, adjusted by Z-Score, Maternal age and BMI, are presented. The greatest contributing contaminants (predictors) that aided in the classification of control vs. cases (mean AUC = 0.65, 95% CI: 0.63–0.67) are shown at the top of the chart. In panel B, the Receiver Operating Characteristic (ROC) and AUC values from stepwise-predictive LRR models (10-fold cross-validation) are shown. An optimal set of five contaminants (predictors) (AUC = 0.67, 95% CI: 0.66–0.68) associated with the classification of control vs. cases are presented.

Table S1. List of contaminants, clusters and their level of identification based on the Metabolomics Standards Initiative (MSI).

Full name	Abbreviation	Cluster	Level of identification
Bisphenol S	BPS	CC1	Level 1
Deoxynivalenol	DON	CC1	Level 1
Monobutyl phthalate	MBP	CC1	Level 2
Perfluorodecanoic acid	PFDA	CC1	Level 1
Methylperfluorooctane sulfonamidoacetic acid	MeFOSAA	CC1	Level 2
Environmental Contaminant 1	EC1	CC1	Level 2
Environmental Contaminant 2	EC2	CC1	Level 2
α -Zearalanol	ZEL	CC1	Level 1
Ethylparaben	EP	CC2	Level 1
Methylparaben	MP	CC2	Level 1
Propylparaben	PP	CC2	Level 1
Perfluorohexanesulfonic acid Branched	PFH _x SBr	CC3	Level 1
Perfluorohexanesulfonic acid	PFH _x S	CC3	Level 1
Perfluorooctanoic acid Branched 1	PFOABr1	CC4	Level 1
Perfluorooctanoic acid Linear 1	PFOAL1	CC4	Level 1
Perfluorooctanoic acid Branched 2	PFOABr2	CC4	Level 1
Perfluorooctanoic acid Linear 2	PFOAL2	CC4	Level 1
Perfluorooctanesulfonic acid Branched	PFOSBr	CC4	Level 1
Perfluorooctanesulfonic acid	PFOS	CC4	Level 1
Environmental Contaminant 3	EC3	CC4	Level 2

Table S2. Two-way analysis of variance (ANOVA) for cord serum lipids (cluster LC1 to LC8) impacted by contaminants exposure (Contaminant cluster CC1 to CC4). The samples were grouped based on contaminants exposure quartiles (1 to 4) and Groups (Control/Cases). The statistical significance levels are represented by p-values ($p < 0.05$ marked bold, p -values < 0.1 in italics).

Contaminant cluster	Lipid cluster	Factor 1: Contaminant quartiles	Factor 2: Groups (Control, Cases)	Interactions F1*F2
CC1	LC1	0.291	0.203	0.467
CC1	LC2	0.271	0.674	0.568
CC1	LC3	9.59×10^{-4}	0.884	0.701
CC1	LC4	6.95×10^{-4}	0.983	0.850
CC1	LC5	0.519	<i>0.055</i>	<i>0.064</i>
CC1	LC6	0.265	0.124	0.111
CC1	LC7	2.03×10^{-2}	0.919	0.936
CC1	LC8	0.869	0.449	0.260
CC2	LC1	0.706	0.195	0.895
CC2	LC2	0.683	0.719	0.471
CC2	LC3	0.814	0.901	0.992
CC2	LC4	0.531	0.973	0.958
CC2	LC5	0.995	<i>0.071</i>	0.947
CC2	LC6	0.731	0.176	0.608
CC2	LC7	<i>0.096</i>	0.960	0.139
CC2	LC8	0.298	0.378	0.917
CC3	LC1	0.578	0.220	0.721
CC3	LC2	0.283	0.803	0.856
CC3	LC3	0.276	0.981	0.730
CC3	LC4	0.581	0.840	0.747
CC3	LC5	1.43×10^{-4}	<i>0.061</i>	0.433
CC3	LC6	3.27×10^{-3}	0.194	0.329
CC3	LC7	0.909	0.967	0.160
CC3	LC8	0.179	0.455	0.919
CC4	LC1	0.249	0.141	<i>0.074</i>
CC4	LC2	0.246	0.534	0.416
CC4	LC3	0.194	0.713	0.027
CC4	LC4	0.221	0.868	0.032
CC4	LC5	0.019	0.026	<i>0.068</i>
CC4	LC6	0.361	0.123	0.348
CC4	LC7	0.172	0.774	0.521
CC4	LC8	<i>0.095</i>	0.296	0.523

Table S3. Post-Hoc test that followed a two-way analysis of variance for cord serum lipids (cluster LC1 to LC8) affected by contaminant exposure (Contaminant cluster CC1 to CC4). The Post-Hoc Tukeys' HSD test was used for pairwise comparison between metabolite levels (along quartiles). The statistical significance levels are indicated by p-values, with values less than 0.05 marked in bold and values less than 0.1 in italics.

Contaminant cluster	Lipid cluster	Factor 1: Contaminant quartiles					
		Q2-Q1	Q3-Q1	Q4-Q1	Q3-Q2	Q4-Q2	Q4-Q3
CC1	LC1	1.000	0.379	0.762	0.371	0.755	0.925
CC1	LC2	0.407	0.820	0.271	0.905	0.994	0.785
CC1	LC3	0.317	0.106	3.68×10⁻⁴	0.942	<i>0.091</i>	0.289
CC1	LC4	0.166	<i>0.081</i>	2.38×10⁻⁴	0.988	0.156	0.292
CC1	LC5	0.991	0.904	0.866	0.980	0.711	0.467
CC1	LC6	0.216	0.659	0.911	0.864	0.585	0.962
CC1	LC7	0.759	0.154	0.018	0.675	0.204	0.837
CC1	LC8	0.988	0.870	0.915	0.971	0.987	0.999
CC2	LC1	0.929	0.952	0.992	0.665	0.988	0.849
CC2	LC2	0.957	0.633	0.864	0.903	0.993	0.977
CC2	LC3	0.986	0.935	0.992	0.788	0.926	0.990
CC2	LC4	0.993	0.694	0.943	0.523	0.839	0.952
CC2	LC5	1.000	0.998	0.998	0.997	0.997	1.000
CC2	LC6	0.968	0.798	0.745	0.968	0.946	1.000
CC2	LC7	0.148	0.989	0.325	0.277	0.975	0.516
CC2	LC8	0.995	0.341	0.640	0.483	0.786	0.961
CC3	LC1	0.609	0.625	0.862	1.000	0.971	0.975
CC3	LC2	0.807	0.220	0.914	0.731	0.995	0.585
CC3	LC3	0.870	0.943	0.729	0.997	0.277	0.384
CC3	LC4	1.000	0.985	0.756	0.977	0.787	0.539
CC3	LC5	0.216	0.343	4.93×10⁻⁵	0.994	0.048	0.024
CC3	LC6	0.490	0.273	0.001	0.979	0.101	0.231
CC3	LC7	0.999	0.983	0.986	0.953	0.998	0.893
CC3	LC8	0.299	0.702	0.174	0.910	0.991	0.772
CC4	LC1	0.969	0.655	0.629	0.376	0.353	1.000
CC4	LC2	0.759	0.826	0.178	0.999	0.718	0.646
CC4	LC3	0.863	0.462	0.167	0.903	0.573	0.932
CC4	LC4	0.812	0.727	0.157	0.999	0.620	0.718
CC4	LC5	0.984	0.215	0.139	0.101	<i>0.059</i>	0.996
CC4	LC6	0.999	0.881	0.470	0.818	0.389	0.895
CC4	LC7	0.993	0.504	0.449	0.345	0.300	1.000
CC4	LC8	0.928	0.754	0.315	0.379	<i>0.093</i>	0.886

Table S4. Two-way analysis of variance (ANOVA) for cord serum polar metabolites (cluster PC1 to PC12) impacted by contaminants exposure (Contaminant cluster CC1 to CC4). The samples were grouped based on contaminants exposure quartiles (1 to 4) and Groups (Control/Cases). The statistical significance levels are represented by p-values ($p < 0.05$ marked bold, p -values < 0.1 in italics).

Contaminant cluster	Polar metabolite cluster	Factor 1: Contaminant quartiles	Factor 2: Groups (Control, Cases)	Interactions F1*F2
CC1	PC1	$<2 \times 10^{-16}$	0.685	0.331
CC1	PC2	$<2 \times 10^{-16}$	0.022	0.516
CC1	PC3	0.780	0.237	0.380
CC1	PC4	3.11×10^{-11}	0.001	0.876
CC1	PC5	0.026	0.554	0.401
CC1	PC6	$<2 \times 10^{-16}$	0.338	0.378
CC1	PC7	0.017	0.726	0.533
CC1	PC8	<i>0.082</i>	0.963	0.533
CC1	PC9	<i>0.085</i>	0.703	0.824
CC1	PC10	1.23×10^{-11}	0.967	0.731
CC1	PC11	4.09×10^{-9}	3.98×10^{-4}	0.544
CC1	PC12	<i>0.068</i>	0.356	0.824
CC2	PC1	0.025	0.574	0.186
CC2	PC2	1.89×10^{-4}	0.097	0.817
CC2	PC3	0.836	0.250	0.723
CC2	PC4	0.021	0.004	0.637
CC2	PC5	0.338	0.498	0.789
CC2	PC6	0.001	0.236	0.446
CC2	PC7	0.006	0.735	0.122
CC2	PC8	0.006	0.631	0.091
CC2	PC9	0.718	0.577	0.250
CC2	PC10	<i>0.051</i>	0.727	0.567
CC2	PC11	0.469	0.004	0.793
CC2	PC12	0.162	0.310	0.011
CC3	PC1	2.02×10^{-6}	0.589	0.829
CC3	PC2	0.131	0.199	0.550
CC3	PC3	0.115	0.259	0.665
CC3	PC4	0.044	0.011	0.515
CC3	PC5	<i>0.095</i>	0.538	0.396
CC3	PC6	0.017	0.160	0.273
CC3	PC7	0.509	0.738	0.004
CC3	PC8	0.002	0.809	0.628
CC3	PC9	0.905	0.591	0.232
CC3	PC10	<i>0.094</i>	0.554	0.953
CC3	PC11	0.044	0.005	0.384
CC3	PC12	0.822	0.318	0.148
CC4	PC1	0.242	0.468	0.861

CC4	PC2	0.376	0.118	0.678
CC4	PC3	0.034	0.143	0.855
CC4	PC4	0.138	0.002	0.666
CC4	PC5	0.027	0.273	0.473
CC4	PC6	0.001	0.398	0.617
CC4	PC7	0.686	0.833	0.032
CC4	PC8	0.010	0.427	0.090
CC4	PC9	0.659	0.738	0.525
CC4	PC10	0.019	0.621	0.943
CC4	PC11	0.183	0.002	0.677
CC4	PC12	0.579	0.401	0.006

Table S5. Post-Hoc test that followed a two-way analysis of variance for cord serum polar metabolites (cluster PC1 to PC12) affected by contaminant exposure (Contaminant cluster CC1 to CC4). The Post-Hoc Tukeys' HSD test was used for pairwise comparison between metabolite levels (along quartiles). The statistical significance levels are indicated by p-values, with values less than 0.05 marked in bold and values less than 0.1 in italics.

Contaminant cluster	Polar metabolite cluster	Factor 1: Contaminant quartiles					
		Q2-Q1	Q3-Q1	Q4-Q1	Q3-Q2	Q4-Q2	Q4-Q3
CC1	PC1	0.002	10^{-8}	10^{-8}	0.021	10^{-8}	0.006
CC1	PC2	10^{-8}	10^{-8}	10^{-8}	0.813	10^{-8}	0.004
CC1	PC3	1.000	0.862	0.998	0.875	0.997	0.773
CC1	PC4	4×10^{-7}	1.84×10^{-4}	10^{-8}	0.571	0.357	0.020
CC1	PC5	0.494	0.653	0.014	0.995	0.362	0.242
CC1	PC6	4.76×10^{-10}	9.10×10^{-13}	8.78×10^{-13}	9.06×10^{-4}	5.71×10^{-7}	0.362
CC1	PC7	0.539	0.853	0.011	0.951	0.288	0.100
CC1	PC8	0.139	0.321	<i>0.096</i>	0.972	0.998	0.930
CC1	PC9	1.000	0.603	0.533	0.665	0.471	0.051
CC1	PC10	2.4×10^{-6}	7×10^{-7}	10^{-8}	0.993	0.155	0.262
CC1	PC11	1.71×10^{-5}	1.93×10^{-4}	10^{-8}	0.950	0.346	0.127
CC1	PC12	0.922	0.918	0.218	0.581	0.564	0.052
CC2	PC1	0.072	0.035	0.690	0.992	0.543	0.375
CC2	PC2	0.998	0.938	0.003	0.869	0.006	3.40×10^{-4}
CC2	PC3	0.978	0.798	0.988	0.957	1.000	0.936
CC2	PC4	0.707	0.974	0.020	0.918	0.252	0.064
CC2	PC5	0.615	0.288	0.877	0.944	0.966	0.737
CC2	PC6	0.066	0.075	0.913	1.000	0.011	0.012
CC2	PC7	0.812	0.522	0.158	0.113	0.621	0.004
CC2	PC8	0.116	0.013	0.011	0.844	0.814	1.000
CC2	PC9	0.988	0.990	0.851	0.923	0.963	0.685
CC2	PC10	0.721	0.669	0.548	1.000	0.085	0.070
CC2	PC11	0.806	0.501	0.998	0.958	0.886	0.610
CC2	PC12	0.883	0.898	0.463	0.481	0.887	0.140
CC3	PC1	0.967	0.002	5.92×10^{-5}	0.008	4.08×10^{-4}	0.850
CC3	PC2	0.125	0.585	0.240	0.790	0.989	0.929
CC3	PC3	0.734	0.495	0.076	0.981	0.506	0.748
CC3	PC4	0.473	0.509	0.983	0.026	0.272	0.741
CC3	PC5	0.924	0.109	0.292	0.359	0.664	0.960
CC3	PC6	0.633	0.325	0.009	0.956	0.199	0.464
CC3	PC7	0.987	0.919	0.721	0.764	0.512	0.977
CC3	PC8	0.820	0.030	0.005	0.229	0.065	0.940
CC3	PC9	0.994	0.996	0.886	1.000	0.965	0.957
CC3	PC10	0.114	0.619	0.149	0.737	0.999	0.803
CC3	PC11	0.601	0.443	0.866	0.034	0.185	0.891

CC3	PC12	0.997	0.800	0.986	0.893	0.999	0.943
CC4	PC1	0.479	0.196	0.713	0.945	0.983	0.794
CC4	PC2	0.988	0.939	0.710	0.994	0.508	0.359
CC4	PC3	0.597	0.854	0.383	0.174	0.025	0.859
CC4	PC4	0.994	0.975	0.229	0.908	0.139	0.453
CC4	PC5	0.981	0.146	0.060	0.302	0.147	0.982
CC4	PC6	0.806	1.000	0.019	0.820	0.001	0.018
CC4	PC7	1.000	0.761	0.934	0.726	0.914	0.980
CC4	PC8	0.637	0.065	0.011	0.565	0.217	0.922
CC4	PC9	0.997	1.000	0.678	0.999	0.801	0.730
CC4	PC10	0.976	0.036	1.000	0.102	0.972	0.035
CC4	PC11	0.918	0.716	0.738	0.975	0.347	0.165
CC4	PC12	0.925	0.998	0.867	0.859	0.505	0.931

Table S6. provides information on the pathways identified through pathway enrichment analysis using MFN pathway maps for controls. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

Name of the pathways	Total size	Hits	Significant hits	Mummichog P values	GSEA P values	Combined P values
Tyrosine metabolism	160	50	40	0.0207	0.0099	0.00195
Tryptophan metabolism	94	31	26	0.02223	0.0198	0.00384
Valine, leucine and isoleucine degradation	65	12	11	0.049	0.0101	0.00426
Pyrimidine metabolism	70	20	17	0.05297	0.0099	0.00449
Urea cycle/amino group metabolism	85	26	21	0.07829	0.01	0.00638
Glycine, serine, alanine and threonine metabolism	88	27	21	0.1365	0.01	0.01037
Butanoate metabolism	34	11	10	0.06911	0.02083	0.01086
Beta-Alanine metabolism	20	9	8	0.1347	0.01099	0.01112
Caffeine metabolism	11	4	4	0.1909	0.01176	0.01594
Fructose and mannose metabolism	33	7	7	0.05475	0.04301	0.01661
Sialic acid metabolism	107	14	11	0.2462	0.01	0.01725
Aminosugars metabolism	69	10	8	0.286	0.01064	0.02068
Propanoate metabolism	31	9	8	0.1347	0.03297	0.02849
Pyruvate Metabolism	20	11	8	0.4575	0.01099	0.03164
Hexose phosphorylation	20	10	7	0.5454	0.01099	0.03667
Methionine and cysteine metabolism	94	17	14	0.1189	0.05941	0.04206
Glutamate metabolism	15	9	8	0.1347	0.05495	0.04371
Selenoamino acid metabolism	35	6	5	0.3404	0.02222	0.04451
Histidine metabolism	33	10	9	0.09685	0.08511	0.0478
Glycosphingolipid metabolism	67	20	15	0.2781	0.0297	0.04787

Table S7. provides information on the pathways identified through pathway enrichment analysis using KEGG pathway maps for controls. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

Name of the pathways	Total size	Hits	Significant hits	Mummichog P values	GSEA P values	Combined P values
Aminoacyl-tRNA biosynthesis	22	14	14	0.0072	0.0101	0.00077
Glycine, serine and threonine metabolism	30	14	14	0.0072	0.0101	0.00077
Tyrosine metabolism	42	21	19	0.02887	0.0099	0.00262
Fructose and mannose metabolism	20	6	6	0.1235	0.0105 ₃	0.00994
Valine, leucine and isoleucine biosynthesis	8	6	6	0.1235	0.0105 ₃	0.00994
Valine, leucine and isoleucine degradation	35	10	9	0.158	0.0101	0.01188
Phenylalanine metabolism	10	8	7	0.2676	0.0101	0.01869
Phenylalanine, tyrosine and tryptophan biosynthesis	4	3	3	0.3529	0.0133 ₃	0.02991
Amino sugar and nucleotide sugar metabolism	35	9	6	0.7479	0.0101	0.04446

Table S8. provides information on the pathways identified through pathway enrichment analysis using MFN pathway maps for cases. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

Name of the pathways	Total size	Hits	Significant hits	Mummichog P values	GSEA P values	Combined P values
Urea cycle/amino group metabolism	85	21	8	0.04279	0.01053	0.00392
Beta-Alanine metabolism	20	9	5	0.01973	0.02469	0.0042
Glutamate metabolism	15	8	4	0.05732	0.0125	0.0059
Glutathione Metabolism	19	4	3	0.02771	0.02817	0.00637
Aminosugars metabolism	69	10	5	0.03316	0.02469	0.00664
Valine, leucine and isoleucine degradation	65	11	5	0.05113	0.02326	0.0092
Alanine and Aspartate Metabolism	30	10	4	0.1235	0.0125	0.01154
Pyruvate Metabolism	20	10	4	0.1235	0.0125	0.01154
Glycerophospholipid metabolism	156	21	7	0.1102	0.02105	0.01639
Glycine, serine, alanine and threonine metabolism	88	25	7	0.2259	0.01064	0.0169
Butanoate metabolism	34	10	4	0.1235	0.02299	0.01949
Carbon fixation	10	2	2	0.04075	0.09524	0.02543
Aspartate and asparagine metabolism	114	30	6	0.591	0.01087	0.03885
Pyrimidine metabolism	70	18	6	0.1357	0.05435	0.04358
Arginine and Proline Metabolism	45	19	5	0.3361	0.02247	0.04445

Table S9. provides information on the pathways identified through pathway enrichment analysis using KEGG pathway maps for cases. It includes the pathways, their corresponding p-values, and the number of metabolites in each pathway, including the total size, hits, and significant hits. The combined p-value was calculated by combining GSEA and Mummichog scores. This table lists only those pathways that have a combined p-value of less than 0.05.

Name of the pathways	Total size	Hits	Significant hits	Mummichog P values	GSEA P values	Combined P values
Aminoacyl-tRNA biosynthesis	22	15	7	0.03758	0.01099	0.00363
Glycine, serine and threonine metabolism	30	14	6	0.08186	0.01124	0.00735
Phosphonate and phosphinate metabolism	4	2	2	0.05452	0.03226	0.01291
Alanine, aspartate and glutamate metabolism	28	12	5	0.1234	0.03448	0.02749
Glyoxylate and dicarboxylate metabolism	31	7	3	0.2106	0.02299	0.03066
Pantothenate and CoA biosynthesis	17	5	3	0.0864	0.05882	0.03193
Glycolysis or Gluconeogenesis	23	3	2	0.1385	0.04286	0.03637
Arginine and proline metabolism	37	19	4	0.6919	0.01099	0.0447